ALNYLAM PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 145.2 USD | -0.11% |
|
-4.56% | -24.16% |
| Apr. 08 | Sector Update: Health Care Stocks Flat to Higher Premarket Monday | MT |
| Apr. 08 | Sector Update: Health Care | MT |
Financials (USD)
| Sales 2024 * | 1.85B | Sales 2025 * | 2.26B | Capitalization | 18.36B |
|---|---|---|---|---|---|
| Net income 2024 * | -515M | Net income 2025 * | -243M | EV / Sales 2024 * | 9.73 x |
| Net cash position 2024 * | 340M | Net cash position 2025 * | 599M | EV / Sales 2025 * | 7.85 x |
| P/E ratio 2024 * |
-35.4
x | P/E ratio 2025 * |
-82.9
x | Employees | 2,100 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.59% |
More Fundamentals
* Assessed data
More news
Latest transcript on Alnylam Pharmaceuticals, Inc.
More recommendations
More press releases
More news
| 1 day | -0.11% | ||
| 1 week | -4.56% | ||
| Current month | -2.87% | ||
| 1 month | -1.53% | ||
| 3 months | -21.94% | ||
| 6 months | -12.07% | ||
| Current year | -24.16% |
1 week
144.23
150.37
1 month
143.66159.34
Current year
143.52199.38
1 year
143.52218.88
3 years
117.58242.97
5 years
65.81242.97
10 years
31.38242.97
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 16-09-18 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 56 | 19-08-12 |
Piyush Sharma
CMP | Compliance Officer | - | 22-09-20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 15-12-17 |
Charles Sigal
BRD | Director/Board Member | 72 | 22-08-21 |
Margaret Hamburg
BRD | Director/Board Member | 68 | 19-01-09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.08% | 1 M€ | 0.00% | - | |
| 4.04% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 145.2 | -0.11% | 398,914 |
| 24-04-17 | 145.3 | -0.95% | 601,282 |
| 24-04-16 | 146.7 | -0.66% | 352,430 |
| 24-04-15 | 147.7 | -0.54% | 498,939 |
| 24-04-12 | 148.5 | -2.36% | 428,052 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Companyâs lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Calendar
2024-04-24
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
145.2
USD
Average target price
220
USD
Spread / Average Target
+51.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.16% | 18.36B | |
| -1.82% | 41.35B | |
| +44.25% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B | |
| -19.38% | 9.78B |
- Stock Market
- Equities
- ALNY Stock
